|
🐜
|
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
29 auth.
John H. Stone,
Peter A. Merkel,
R. Spiera,
P. Seo,
C. Langford,
G. Hoffman,
C. Kallenberg,
E. St. Clair,
A. Turkiewicz,
N. Tchao,
L. Webber,
L. Ding,
Lourdes P. Sejismundo,
Kathleen Mieras,
D. Weitzenkamp,
...
D. Ikle,
V. Seyfert-Margolis,
Mark Mueller,
P. Brunetta,
Nancy B. Allen,
F. Fervenza,
D. Geetha,
K. Keogh,
E. Kissin,
P. Monach,
T. Peikert,
C. Stegeman,
S. Ytterberg,
U. Specks
|
11 |
2010 |
11
🐜
|
|
🐜
|
Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study
13 auth.
Peter A. Merkel,
Grace H. Lo,
Janet T. Holbrook,
A. Tibbs,
Nancy B. Allen,
John C. Davis,
G. Hoffman,
W. J. Mccune,
E. St. Clair,
U. Specks,
...
R. Spiera,
M. Petri,
John H. Stone
|
7 |
2005 |
7
🐜
|
|
🐜
|
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
28 auth.
Eli M. Miloslavsky,
U. Specks,
P. Merkel,
Philip Seo,
R. Spiera,
C. Langford,
G. Hoffman,
C. Kallenberg,
E. Clair,
N. Tchao,
L. Viviano,
L. Ding,
Lourdes P. Sejismundo,
Kathleen Mieras,
David Ikle,
...
B. Jepson,
Mark Mueller,
P. Brunetta,
Nancy B. Allen,
F. Fervenza,
D. Geetha,
K. Keogh,
E. Kissin,
P. Monach,
Tobias Peikert,
C. Stegeman,
S. Ytterberg,
John H. Stone
|
6 |
2013 |
6
🐜
|
|
🐜
|
Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
8 auth.
Peter J. Conlon,
C. A. Fischer,
Marc C. Levesque,
Stephen R. Smith,
E. Clair,
Nancy B. Allen,
...
J. Fleming,
David N. Howell
|
5 |
1996 |
5
🐜
|
